BUZZ-Apellis Pharmaceuticals falls on wider-than-expected Q3 loss

Reuters11-05

** Shares of biopharmaceutical firm Apellis Pharmaceuticals

fall 8.9% to $26.02

** APLS opens at near three-month low

** Co reports wider-than-expected loss in Q3

** Q3 loss at 46 cents/shr vs. estimates of loss of 30 cents/shr - LSEG

** Co reported Q3 rev of $196.8 mln vs. estimates of $200.35 mln - LSEG

** APLS's SYFOVRE injection, which treats a macular degeneration disorder called geographic atrophy (GA) received a negative opinion from the Committee for Medicinal Products for Human Use $(CHMP)$ in September

** SYFOVRE net selling price declined relative to previous quarters due to an increase in gross-to-net adjustments - APLS

** Co also expect regulatory decisions in the U.K., Switzerland, Canada and Australia in early 2025 for SYFORVE

** 15 of 21 analysts that cover APLS rate the stock "buy" or higher, 6 "hold", median PT is $68 - LSEG

** As of last close, stock down ~52% YTD

(Reporting by Ragini Mathur)

((Ragini.Mathur@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment